Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome

Archives of Cardiovascular Diseases

Volumn 103, Issue 5, 2010, Pages 317-325

  Detaint, Delphine ^a   Aegerter, Philippe ^b   Tubach, Florence ^c   Hoffman, Isabelle ^c   Plauchu, Henri ^d   Dulac, Yves ^e   Faivre, Laurence Olivier ^f   Delrue, Marie Ange ^g   Collignon, Patrick ^h   Odent, Sylvie ⁱ   Tchitchinadze, Maria ^a   Bouffard, Catherine ^a   Arnoult, Florence ^a   Gautier, Mathieu ^a   Boileau, Catherine ^a,j   Jondeau, Guillaume ^a,c  

^a BICHAT HOSPITAL   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c INSERM   (France)

^d UNIVERSITÉ LYON 1   (France)

^e HÔPITAL DES ENFANTS   (France)

^f UNIVERSITÉ DE BOURGOGNE   (France)

^g HÔPITAL PELLEGRIN   (France)

^h TIMONE HOSPITAL   (France)

ⁱ SERVICE DE RHUMATOLOGIE   (France)

^j HÔPITAL AMBROISE PARÉ   (France)

more..

Author keywords

Angiotensin II receptor blocker; Aorta; Aortic aneurysm; Thoracic; Transforming growth factor beta

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PLACEBO; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; AORTA DISSECTION; AORTA ROOT; AORTIC ROOT SURGERY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DILATATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERANCE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MARFAN SYNDROME; MOUSE; MULTICENTER STUDY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; TWO DIMENSIONAL ECHOCARDIOGRAPHY; ANIMAL; AORTIC ANEURYSM; COMPLICATION; DISEASE MODEL; ECHOGRAPHY; FRANCE; METHODOLOGY; PLACEBO EFFECT; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTIC ANEURYSM; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; FRANCE; HUMANS; LOSARTAN; MARFAN SYNDROME; MICE; PLACEBO EFFECT; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 77956652235     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2010.04.008     Document Type: Article

References (42)

1. P. Beighton, A. de Paepe, and D. Danks International nosology of heritable disorders of connective tissue, Berlin, 1986 Am J Med Genet 29 1988 581 594
2. A. De Paepe, R.B. Devereux, and H.C. Dietz Revised diagnostic criteria for the Marfan syndrome Am J Med Genet 62 1996 417 426
3. B.L. Loeys, U. Schwarze, and T. Holm Aneurysm syndromes caused by mutations in the TGF-beta receptor N Engl J Med 355 2006 788 798
4. L. Faivre, G. Collod-Beroud, and B.L. Loeys Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study Am J Hum Genet 81 2007 454 466
5. D. Attias, C. Stheneur, and C. Roy Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders Circulation 120 2009 2541 2549
6. C. Boileau, G. Jondeau, and M.C. Babron Autosomal dominant Marfan-like connective-tissue disorder with aortic dilation and skeletal anomalies not linked to the fibrillin genes Am J Hum Genet 53 1993 46 54
7. C. Boileau, G. Jondeau, and T. Mizuguchi Molecular genetics of Marfan syndrome Curr Opin Cardiol 20 2005 194 200
8. B.L. Loeys, J. Chen, and E.R. Neptune A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2 Nat Genet 37 2005 275 281
9. M. Pepin, U. Schwarze, and A. Superti-Furga Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type N Engl J Med 342 2000 673 680
10. C.J. Vaughan, M. Casey, and J. He Identification of a chromosome 11q23.2-q24 locus for familial aortic aneurysm disease, a genetically heterogeneous disorder Circulation 103 2001 2469 2475
11. V.L. Gott, P.S. Greene, and D.E. Alejo Replacement of the aortic root in patients with Marfan's syndrome N Engl J Med 340 1999 1307 1313
12. M.E. Legget, T.A. Unger, and C.K. O'Sullivan Aortic root complications in Marfan's syndrome: identification of a lower risk group Heart 75 1996 389 395
13. M.G. Keane, and R.E. Pyeritz Medical management of Marfan syndrome Circulation 117 2008 2802 2813
14. B.L. Halpern, F. Char, and J.L. Murdoch A prospectus on the prevention of aortic rupture in the Marfan syndrome with data on survivorship without treatment Johns Hopkins Med J 129 1971 123 129
15. J. Shores, K.R. Berger, and E.A. Murphy Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome N Engl J Med 330 1994 1335 1341
16. M. Ladouceur, C. Fermanian, and J.M. Lupoglazoff Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome Am J Cardiol 99 2007 406 409
17. R. Rossi-Foulkes, M.J. Roman, and S.E. Rosen Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome Am J Cardiol 83 1999 1364 1368
18. G. Jondeau, P. Boutouyrie, and P. Lacolley Central pulse pressure is a major determinant of ascending aorta dilation in Marfan syndrome Circulation 99 1999 2677 2681
19. M. Groenink, A. de Roos, and B.J. Mulder Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome Am J Cardiol 82 1998 203 208
20. R.W. Jeremy, H. Huang, and J. Hwa Relation between age, arterial distensibility, and aortic dilatation in the Marfan syndrome Am J Cardiol 74 1994 369 373
21. G.J. Nollen, K.E. van Schijndel, and J. Timmermans Magnetic resonance imaging of the main pulmonary artery: reliable assessment of dimensions in Marfan patients on a simple axial spin echo image Int J Cardiovasc Imaging 19 2003 141 147 [discussion 49-50]
22. A. Haouzi, H. Berglund, and P.C. Pelikan Heterogeneous aortic response to acute beta-adrenergic blockade in Marfan syndrome Am Heart J 133 1997 60 63
23. A.S. Rios, E.N. Silber, and N. Bavishi Effect of long-term beta-blockade on aortic root compliance in patients with Marfan syndrome Am Heart J 137 1999 1057 1061
24. F.C. Yin, K.P. Brin, and C.T. Ting Arterial hemodynamic indexes in Marfan's syndrome Circulation 79 1989 854 862
25. L.F. Borges, Z. Touat, and A. Leclercq Tissue diffusion and retention of metalloproteinases in ascending aortic aneurysms and dissections Hum Pathol 40 2009 306 313
26. P.W. Fedak, S. Verma, and T.E. David Clinical and pathophysiological implications of a bicuspid aortic valve Circulation 106 2002 900 904
27. D. Gomez, A. Al Haj Zen, and L.F. Borges Syndromic and non-syndromic aneurysms of the human ascending aorta share activation of the Smad2 pathway J Pathol 218 2009 131 142
28. A.W. Chung, K. Au Yeung, and G.G. Sandor Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in the thoracic aortic aneurysm in Marfan syndrome Circ Res 101 2007 512 522
29. D.P. Judge, N.J. Biery, and D.R. Keene Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome J Clin Invest 114 2004 172 181
30. S.S. Chaudhry, S.A. Cain, and A. Morgan Fibrillin-1 regulates the bioavailability of TGFbeta1 J Cell Biol 176 2007 355 367
31. Z. Isogai, R.N. Ono, and S. Ushiro Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein J Biol Chem 278 2003 2750 2757
32. E.R. Neptune, P.A. Frischmeyer, and D.E. Arking Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome Nat Genet 33 2003 407 411
33. J.P. Habashi, D.P. Judge, and T.M. Holm Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome Science 312 2006 117 121
34. C.M. Ng, A. Cheng, and L.A. Myers TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome J Clin Invest 114 2004 1586 1592
35. B.S. Brooke, J.P. Habashi, and D.P. Judge Angiotensin II blockade and aortic-root dilation in Marfan's syndrome N Engl J Med 358 2008 2787 2795
36. A.A. Ahimastos, A. Aggarwal, and K.M. D'Orsa Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial JAMA 298 2007 1539 1547
37. A.T. Yetman, R.A. Bornemeier, and B.W. McCrindle Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome Am J Cardiol 95 2005 1125 1127
38. R.V. Lacro, H.C. Dietz, and L.M. Wruck Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome Am Heart J 154 2007 624 631
39. F.I. Gambarin, V. Favalli, and A. Serio Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations J Cardiovasc Med (Hagerstown) 10 2009 354 362
40. M.J. Roman, R.B. Devereux, and R. Kramer-Fox Two-dimensional echocardiographic aortic root dimensions in normal children and adults Am J Cardiol 64 1989 507 512
41. M. Gautier, D. Detaint, and C. Fermanian Nomograms for aortic root diameters in children using two-dimensional echocardiography Am J Cardiol 105 2010 888 894
42. P. ten Dijke, and H.M. Arthur Extracellular control of TGFbeta signalling in vascular development and disease Nat Rev Mol Cell Biol 8 2007 857 869